Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Randomized, Double-Blind, First-in-Human Study of T-ACE Oil by Trans-Catheter Arterial Embolization or ChemoEmbolization (TAE/TACE) in Patients With Hepatocellular Carcinoma

NCT05435014 is registered in ClinicalTrials.gov with T-ACE Medical Co., Ltd as lead sponsor.

NCT NCT05435014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05435014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Randomized, Double-Blind, First-in-Human Study of T-ACE Oil by Trans-Catheter Arterial Embolization or ChemoEmbolization (TAE/TACE) in Patients With Hepatocellular Carcinoma
Lead sponsor
T-ACE Medical Co., Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
September 13, 2022
Completion date
June 15, 2026
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma